Clinical Trial Update: Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab after radiotherapy in patients with oligometastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma
• Oligometastasis

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Nasopharyngeal Carcinoma, Oligometastasis | Phase 2 | Status: UNKNOWN